ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of “Moderate Buy” from Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $7.1429.

A number of equities analysts have weighed in on the stock. Zacks Research upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Wednesday, October 8th.

Institutional Investors Weigh In On ProQR Therapeutics

Several large investors have recently made changes to their positions in the company. Osaic Holdings Inc. lifted its position in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,500 shares during the last quarter. Moody Lynn & Lieberson LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $50,000. Fifth Third Bancorp purchased a new position in shares of ProQR Therapeutics in the 3rd quarter valued at $64,000. Vontobel Holding Ltd. grew its stake in ProQR Therapeutics by 76.5% in the second quarter. Vontobel Holding Ltd. now owns 63,979 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 27,722 shares during the last quarter. Finally, OneDigital Investment Advisors LLC grew its position in shares of ProQR Therapeutics by 23.1% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 80,000 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 15,000 shares during the last quarter. 32.65% of the stock is owned by institutional investors.

ProQR Therapeutics Stock Performance

NASDAQ PRQR opened at $1.58 on Friday. The business’s fifty day moving average is $2.10 and its 200 day moving average is $2.23. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $3.10. The company has a market capitalization of $166.23 million, a PE ratio of -3.36 and a beta of 0.19.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The company had revenue of $3.38 million during the quarter, compared to the consensus estimate of $7.05 million. ProQR Therapeutics had a negative return on equity of 58.70% and a negative net margin of 273.20%. On average, sell-side analysts forecast that ProQR Therapeutics will post -0.31 EPS for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.